AU2007235145B2 - Combination treatment of metabolic disorders - Google Patents

Combination treatment of metabolic disorders Download PDF

Info

Publication number
AU2007235145B2
AU2007235145B2 AU2007235145A AU2007235145A AU2007235145B2 AU 2007235145 B2 AU2007235145 B2 AU 2007235145B2 AU 2007235145 A AU2007235145 A AU 2007235145A AU 2007235145 A AU2007235145 A AU 2007235145A AU 2007235145 B2 AU2007235145 B2 AU 2007235145B2
Authority
AU
Australia
Prior art keywords
hydrogen
compound
methyl
diabetes
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007235145A
Other languages
English (en)
Other versions
AU2007235145A1 (en
Inventor
Kirvin L. Hodge
Reid W. Von Borstel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of AU2007235145A1 publication Critical patent/AU2007235145A1/en
Application granted granted Critical
Publication of AU2007235145B2 publication Critical patent/AU2007235145B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007235145A 2006-03-31 2007-03-05 Combination treatment of metabolic disorders Ceased AU2007235145B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74402106P 2006-03-31 2006-03-31
US60/744,021 2006-03-31
PCT/US2007/063288 WO2007117791A2 (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
AU2007235145A1 AU2007235145A1 (en) 2007-10-18
AU2007235145B2 true AU2007235145B2 (en) 2011-09-22

Family

ID=38581719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007235145A Ceased AU2007235145B2 (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Country Status (11)

Country Link
US (1) US8338480B2 (enExample)
EP (1) EP2001461A4 (enExample)
JP (1) JP2009532372A (enExample)
KR (1) KR20080106455A (enExample)
CN (1) CN101410105A (enExample)
AU (1) AU2007235145B2 (enExample)
CA (1) CA2647258A1 (enExample)
IL (1) IL194189A0 (enExample)
MX (1) MX2008012506A (enExample)
NZ (1) NZ571118A (enExample)
WO (1) WO2007117791A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101059776B1 (ko) * 2001-06-12 2011-08-26 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
US8022249B2 (en) 2005-04-01 2011-09-20 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
MX2010002562A (es) * 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
AU2009258040B8 (en) * 2008-03-13 2014-04-24 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
CN104885151B (zh) 2012-12-21 2017-12-22 杜比实验室特许公司 用于基于感知准则呈现基于对象的音频内容的对象群集
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
JP6553375B2 (ja) * 2014-06-24 2019-07-31 花王株式会社 Ｕｃｐ−１発現促進剤
JP6660668B2 (ja) * 2014-06-24 2020-03-11 花王株式会社 Ｕｃｐ−１発現促進剤
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ｕｃｐ－１発現促進剤
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
EP3288389A4 (en) 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
IL158873A0 (en) * 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA05011042A (es) * 2003-04-15 2005-12-15 Wellstat Therapeutics Corp Compuestos para el tratamieno de trastornos metabolicos.
WO2004093806A2 (en) * 2003-04-22 2004-11-04 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN100348186C (zh) * 2003-04-30 2007-11-14 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
BRPI0413758A (pt) * 2003-08-20 2006-10-31 Wellstat Therapeutics Corp compostos para o tratamento de transtornos metabólicos
US8022249B2 (en) * 2005-04-01 2011-09-20 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
JP2009528275A (ja) 2006-01-25 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
WO2007087505A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US6858602B2 (en) * 2001-06-12 2005-02-22 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
WO2007117791A3 (en) 2008-08-21
KR20080106455A (ko) 2008-12-05
CN101410105A (zh) 2009-04-15
EP2001461A2 (en) 2008-12-17
US8338480B2 (en) 2012-12-25
IL194189A0 (en) 2009-08-03
AU2007235145A1 (en) 2007-10-18
CA2647258A1 (en) 2007-10-18
EP2001461A4 (en) 2010-06-09
NZ571118A (en) 2011-12-22
WO2007117791A2 (en) 2007-10-18
US20100292277A1 (en) 2010-11-18
MX2008012506A (es) 2008-10-14
JP2009532372A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
AU2007235145B2 (en) Combination treatment of metabolic disorders
US7645772B2 (en) Treatment of metabolic disorders
JP2019524808A (ja) アモジアキンおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
JP2011219496A (ja) 高脂血症又はインスリン非依存性糖尿病の予防及び／又は治療のための医薬
JP2000514807A (ja) レプチン耐性の新規な治療
AU2003299772C1 (en) Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
AU2001277926B2 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
KR100798217B1 (ko) 당뇨병을 치료하기 위한 피탄산의 용도
MX2008015640A (es) Compuestos para el tratamiento de trastornos metabolicos.
AU2001277926A1 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
WO2006001092A1 (ja) インスリン分泌促進剤
KR102524408B1 (ko) 아모디아퀸 및 아르테수네이트계 약물을 유효성분으로 함유하는 제2형 당뇨병 예방 또는 치료용 약학적 조성물
JP2005514399A (ja) ＰＰＡＲγアクチベーターの投薬法
AU2003260380B2 (en) Use of a PPAR-alpha agonist to treat weight gain associated with a PPAR-gamma agonist treatment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired